secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2026-06-30T20:30:25+00:00
Accession:  0001193125-26-290661
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics enters supply agreement with Orion; extends regulatory approval deadline to 2035
--------------------------------------------------------------------------------

- Supply Agreement with Orion for oral levosimendan; 5-year initial term, auto-renewing 3-year periods.
- Sixth Amendment extends U.S. regulatory approval deadline to December 31, 2035; failure allows termination.
- Company must comply with Orion's General Information and Cybersecurity Requirements as part of amendment.
- Supply Agreement includes cost-sharing provisions for scaling Orion's manufacturing capabilities.
- Either party may terminate for material breach (60-day cure) or insolvency; also tied to License Agreement termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000119312526290661/0001193125-26-290661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000119312526290661/d117070d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-290661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer